Allen Institute

Allen Institute, a nonprofit research organization headquartered in Seattle, Washington, receives federal grant funding as a prime recipient for large-scale neuroscience research spanning brain cell type characterization, connectomics, and immunology. The Institute operates across multiple NIH institutes and centers, with no federal contract presence; all transacting is through cooperative agreements and project grants under CFDA 93.x programs.

Allen Institute's federal footprint concentrates in three NIH customer agencies that account for 74 percent of recent awards by count: the National Institute of Mental Health (36 awards as prime recipient), the National Institute of Neurological Disorders and Stroke (24 awards), and the National Institute on Aging (15 awards). The National Institute on Drug Abuse anchors the dollar value with four awards carrying combined potential value of $22 million; this concentration reflects the Institute's role as lead recipient on multi-million-dollar collaborative projects under the Brain Initiative and related trans-NIH programs. The Institute also receives subcontract work as a sub-recipient under prime grantees including Harvard University, University of Washington, Baylor College of Medicine, and others, supporting specific data-generation or analytical components of larger consortia. Recent sub awards include work on Alzheimer's disease mechanisms under University of California, San Francisco prime awards, developmental brain cell atlases under Harvard prime agreements, and immunology service cores under Seattle Children's Hospital-led U19 programs.

Allen Institute's capability portfolio centers on four concrete domains, each anchored in recent prime awards. First, whole-brain cell type atlases: the Institute received a $1.88 million NIMH project grant (CFDA 93.242) awarded March 2026 for single-cell genomic mapping of brainstem cell types, and carries multiple cooperative agreements (CFDA 93.372) from the National Institute of Neurological Disorders and Stroke funding light-sheet microscopy development, electron microscopy connectomics pipelines, and brain-wide neuronal projection mapping. Second, connectomics and circuit mapping: the Institute holds several NINDS BRAIN Initiative Connectivity Across Scales (BRAIN Connects) cooperative agreements (CFDA 93.372) funding electron microscopy reconstruction pipelines, light-microscopy-based connectivity imaging, and barcoded sequencing approaches for neural projection mapping in mouse and non-human primate brains. Third, computational modeling and data infrastructure: the Institute received a $1.27 million NIH Office of the Director project grant (CFDA 93.310) awarded September 2024 for exa-scale tissue readout methods, and holds long-standing cooperative agreements for the Brain Modeling Toolkit, SONATA data format, and brain knowledge base platforms. Fourth, immunology research: the Institute for Immunology receives sub-award funding from Seattle Children's Hospital (U19 cooperative agreements) to operate integrative multi-omics service cores performing single-cell transcriptomics, flow cytometry, and plasma proteomics on immune samples from disease cohorts.

Activity trajectory shows sustained volume with recent growth: 13 awards in 2022, 11 in 2023, 22 in 2024, and 22 in 2025, with four awards recorded in the first five months of 2026. Seventeen awards carry completion dates within the next twenty-four months, marking recompete exposure. The Institute's dollar-to-award ratio (combined obligated of $1.04 billion against combined potential value of $22 million) reflects the structure of large, multi-year cooperative agreements with upfront obligation of full funding; this is consistent with NIH Research Scientist cooperative agreement accounting practices. The Institute competes exclusively in open (non-set-aside) federal grant programs; all funding derives from competitive peer-reviewed processes managed by NIH institutes and centers or collaborative consortia like the Brain Initiative.